FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to fused proteins that contain IL-2 receptor-binding fragment and ST2-binding fragment; it can be used in medicine for the treatment of inflammatory myopathy, inflammatory condition of adipose tissue, inflammatory condition of the intestine, inflammatory condition of the lungs and autoimmune disease. Fused protein contains human IL-2 protein, immunoglobulin Fc protein, and protein that binds to interleukin-1 receptor-like protein 1 (ST2), selected from human IL-33 protein, an antibody specific to ST2, or its antigen-binding fragment. Dimer of the specified fused protein is also proposed.
EFFECT: invention provides for the selective activation of ST2+ regulatory T-cell compared to ST2- regulatory T-cell in an individual.
46 cl, 11 dwg, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| COMPOSITION FOR ANTICANCER TREATMENT CONTAINING NK-CELLS AND FUSION PROTEIN WHICH CONTAINS IL-2 PROTEIN AND CD80 PROTEIN | 2020 |
|
RU2832136C1 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) | 2015 |
|
RU2829846C2 |
